55.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$55.44
Aprire:
$56.45
Volume 24 ore:
1.13M
Relative Volume:
0.71
Capitalizzazione di mercato:
$5.36B
Reddito:
$4.10M
Utile/perdita netta:
$-568.53M
Rapporto P/E:
-8.9233
EPS:
-6.2118
Flusso di cassa netto:
$-401.18M
1 W Prestazione:
+2.21%
1M Prestazione:
-2.62%
6M Prestazione:
+11.96%
1 anno Prestazione:
-23.88%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
CRSP
Crispr Therapeutics Ag
|
55.43 | 5.24B | 4.10M | -568.53M | -401.18M | -6.2118 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | JP Morgan | Overweight |
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - uk.finance.yahoo.com
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock forecasts - Yahoo Finance Singapore
Total common shares outstanding of CRISPR Therapeutics AG – HAN:1CG - TradingView
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? - The Motley Fool
CRISPR Therapeutics stock price target reaffirmed at $80 by Citizens - Investing.com
One CRISPR treatment cut “bad” cholesterol in half for a full year - ScienceDaily
Form 144 CRISPR THERAPEUTICS AG For: 27 September By Investing.com - Investing.com Nigeria
Crispr Therapeutics AG (CRSP) Stock Price Today: $54.23 - Pluang
CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - Stocktwits
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
CRISPR Therapeutics stock analysis: pipeline catalysts vs. financial reality - Investing.com
Form 4 CRISPR Therapeutics AG For: 24 September By Investing.com - Investing.com Canada
Form 4 CRISPR Therapeutics AG For: 24 September - Investing.com India
CRISPR Therapeutics' General Counsel James R. Kasinger Sells 10,400 Shares Following Option Exercise - Kalkine Media
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics' Casgevy sales jump 78% in Q2, boosting long-term buy case despite AI gene editing risks - Pluang
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP) - Seeking Alpha
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme D - GuruFocus
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
CRISPR Therapeutics stock trades below targets despite approved gene therapy; analyst sees 85% upside potential. - Pluang
CRISPR Therapeutics AG (CRSP) Options ChainYahoo Finance - Yahoo! Finance Canada
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - uk.finance.yahoo.com
What Put the CRISPR Therapeutics (CRSP) Story on the Radar? - Kalkine Media
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know - Yahoo Finance
Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 - Stock Titan
Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution - Stock Titan
Why CRISPR Therapeutics (CRSP) Is Back In The Spotlight - simplywall.st
New Treatment Cuts “Bad” Cholesterol in Half for a Full Year - SciTechDaily
CRISPR Therapeutics stock edges lower as investors digest latest pipeline and earnings figures - AD HOC NEWS
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 - The Motley Fool
Crispr Therapeutics' Diverse Gene Editing Portfolio Supports Positive Long-Term Outlook - Morningstar
CRISPR Therapeutics AG (CRSP) Stock Forecasts - Yahoo Finance
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - TradingView
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP): What's Behind Its Stock Surge? - Kalkine Media
Director at CRISPR Therapeutics (NASDAQ: CRSP) files notice for six-figure stock sale - Stock Titan
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.6%What's Next? - MarketBeat
CRISPR Therapeutics Surges 11.39% as CRSP Stock Breaks Above $58RSI Oversold Picks - careplusvn.com
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? - Yahoo Finance
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crispr Therapeutics Ag Azioni (CRSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KASINGER JAMES R. | General Counsel and Secretary |
Sep 22 '26 |
Sale |
60.24 |
10,400 |
626,460 |
94,784 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):